Nerve Growth Factor and Diabetic Neuropathy
Authors:
Open Access
- 1 January 2003
- journal article
- research article
- Published by Wiley in Journal of Diabetes Research
- Vol. 4 (4) , 271-285
Abstract
Neuropathy is one of the most debilitating complications of both type 1 and type 2 diabetes, with estimates of prevalence between 50–90% depending on the means of detection. Diabetic neuropathies are heterogeneous and there is variable involvement of large myelinated fibers and small, thinly myelinated fibers. Many of the neuronal abnormalities in diabetes can be duplicated by experimental depletion of specific neurotrophic factors, their receptors or their binding proteins. In experimental models of diabetes there is a reduction in the availability of these growth factors, which may be a consequence of metabolic abnormalities, or may be independent of glycemic control. These neurotrophic factors are required for the maintenance of the neurons, the ability to resist apoptosis and regenerative capacity. The best studied of the neurotrophic factors is nerve growth factor (NGF) and the related members of the neurotrophin family of peptides. There is increasing evidence that there is a deficiency of NGF in diabetes, as well as the dependent neuropeptides substance P (SP) and calcitonin gene‐related peptide (CGRP) that may also contribute to the clinical symptoms resulting from small fiber dysfunction. Similarly, NT3 appears to be important for large fiber and IGFs for autonomic neuropathy. Whether the observed growth factor deficiencies are due to decreased synthesis, or functional, e.g. an inability to bind to their receptor, and/or abnormalities in nerve transport and processing, remains to be established. Although early studies in humans on the role of neurotrophic factors as a therapy for diabetic neuropathy have been unsuccessful, newer agents and the possibilities uncovered by further studies should fuel clinical trials for several generations. It seems reasonable to anticipate that neurotrophic factor therapy, specifically targeted at different nerve fiber populations, might enter the therapeutic armamentarium.Keywords
This publication has 92 references indexed in Scilit:
- Experimental diabetic neuropathy: an updateDiabetologia, 1999
- Lysosomal Proteolysis of Prosaposin, the Precursor of Saposins (Sphingolipid Activator Proteins): Its Mechanism and Inhibition by GangliosideArchives of Biochemistry and Biophysics, 1997
- Nerve Growth Factor and Oxidative Stress in the Nervous System1997
- trkC encodes multiple neurotrophin‐3 receptors with distinct biological properties and substrate specificities.The EMBO Journal, 1993
- Use of a digital brain atlas to compare the distribution of NGF‐ and bFGF‐protected cholinergic neuronsJournal of Comparative Neurology, 1991
- Rationale for the Planned Clinical Trials with Nerve Growth Factor in Alzheimer’s Disease1990
- Death of some dorsal root ganglion neurons and plasticity of others following sciatic nerve section in adult and neonatal ratsJournal of Comparative Neurology, 1989
- The nerve growth factor: thirty‐five years later.The EMBO Journal, 1987
- Nerve growth factor protects adult sensory neurons from cell death and atrophy caused by nerve injuryJournal of Neurocytology, 1987
- Selective growth stimulating effects of mouse sarcoma on the sensory and sympathetic nervous system of the chick embryoJournal of Experimental Zoology, 1951